Medical isotope producer Advanced Medical Isotope (AMIC) of Kennewick, WA, has signed an exclusive worldwide license for brachytherapy seed technology for enhanced delivery of radionuclides to cancer tissue.
The resorbable seed is designed to provide controlled delivery of insoluble yttrium-90 microspheres to cancer sites. The new seed is a joint invention by radiochemists and medical physicists at Battelle in Richland, WA, and pharmaceutical chemists at the University of Utah in Salt Lake City.
AMIC is testing and conducting research to develop the new brachytherapy seed, and the company anticipates filing a 510(k) application with the U.S. Food and Drug Administration as soon as this month.
AMIC anticipates the seed will be used for prostate cancer and other radiation-resistant cancers, such as brain tumors, head and neck tumors, and liver cancer.
Related Reading
AMIC moves isotope project forward, June 4, 2010
AMIC tests new Mo-99 technology, November 4, 2009
AMIC, MU partner on Mo-99 device, June 15, 2009
AMIC teams with DoE on isotopes, January 26, 2009
AMIC blames Washington client, August 6, 2008
Copyright © 2010 AuntMinnie.com
_p888_f1_thumb.png?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
